The Company remains on track to complete 12-month visits by early Q2 2027. Envoy Medical has submitted two of the four ...
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
Favorable interim safety and tolerability profile observed across single and multiple ascending dose cohorts in healthy ...
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, ...
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 ...
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non ...
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based ...
Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming ...
VANCOUVER, BC / ACCESS Newswire / October 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results